Menu Search
Equities

InDex Pharmaceuticals Holding AB

1NP:BER

InDex Pharmaceuticals Holding AB

Actions
  • Price (EUR)0.0414
  • Today's Change0.006 / 16.95%
  • Shares traded-1.00
  • 1 Year change+18.29%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 20:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

  • Revenue in SEK (TTM)108.34m
  • Net income in SEK-56.48m
  • Incorporated2016
  • Employees7.00
  • Location
    InDex Pharmaceuticals Holding ABBerzelius Vag 13SOLNA 171 65SwedenSWE
  • Phone+46 812203850
  • Fax+46 850884739
  • Websitehttps://www.indexpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.